O	0	1	[
O	1	12	Neoadjuvant
O	13	22	treatment
O	23	26	for
O	27	34	locally
O	35	43	advanced
O	44	50	breast
O	51	57	cancer
O	57	58	.
O	59	69	Comparison
O	70	72	of
O	73	76	two
O	77	84	schemes
O	85	90	based
O	91	93	on
B-intervention	94	103	docetaxel
I-intervention	103	104	-
I-intervention	104	114	epirubicin
O	115	117	vs
O	117	118	.
B-control	119	120	5
I-control	120	121	-
I-control	121	133	fluorouracil
I-control	133	134	-
I-control	134	144	epirubicin
I-control	144	145	-
I-control	145	161	cyclophosphamide
O	161	162	]
O	162	163	.

O	164	170	Breast
O	171	177	cancer
O	178	180	is
O	181	184	the
O	185	189	most
O	190	196	common
O	197	201	type
O	202	204	of
O	205	211	cancer
O	212	214	in
O	215	220	women
O	221	230	worldwide
O	230	231	.

O	232	234	In
B-location	235	241	Mexico
O	241	242	,
O	243	244	>
O	244	246	34
O	246	247	%
O	248	250	of
O	251	259	patients
O	260	263	are
O	264	266	in
O	267	274	locally
O	275	283	advanced
O	284	290	stages
O	291	293	at
O	294	297	the
O	298	302	time
O	303	305	of
O	306	315	diagnosis
O	315	316	.

O	317	328	Neoadjuvant
O	329	341	chemotherapy
O	342	344	is
O	345	357	administered
O	358	360	to
O	361	368	control
O	369	374	local
O	375	382	disease
O	382	383	,
O	384	388	make
O	389	397	surgical
O	398	407	resection
O	408	416	possible
O	417	420	and
O	421	429	increase
O	430	433	the
O	434	445	possibility
O	446	448	of
O	449	455	breast
O	456	462	tissue
O	463	475	conservation
O	475	476	.

O	477	479	We
O	480	489	performed
O	490	491	a
O	492	498	double
O	498	499	-
O	499	504	blind
O	504	505	,
O	506	516	randomized
O	517	525	clinical
O	526	531	trial
O	532	534	in
B-eligibility	535	543	patients
I-eligibility	544	548	with
I-eligibility	549	556	locally
I-eligibility	557	565	advanced
I-eligibility	566	572	breast
I-eligibility	573	579	cancer
I-eligibility	580	581	(
I-eligibility	581	587	stages
I-eligibility	588	591	IIB
I-eligibility	592	595	and
I-eligibility	596	600	IIIA
I-eligibility	600	601	)
O	602	606	with
O	607	610	two
O	611	618	therapy
O	619	626	schemes
O	626	627	;
B-control	628	629	5
I-control	629	630	-
I-control	630	642	fluorouracil
I-control	642	643	-
I-control	643	653	epirubicin
I-control	653	654	-
I-control	654	670	cyclophosphamide
I-control	671	672	(
I-control	672	679	control
I-control	680	685	group
I-control	685	686	)
O	687	689	vs
O	689	690	.
O	691	700	docetaxel
O	700	701	-
O	701	711	epirubicin
O	712	713	(
O	713	718	study
O	719	724	group
O	724	725	)
O	725	726	.

O	727	731	Both
O	732	736	were
O	737	746	indicated
O	747	749	in
O	750	755	three
O	756	768	preoperative
O	769	775	cycles
O	775	776	,
O	777	780	and
O	781	789	patients
O	790	794	were
O	795	804	submitted
O	805	815	afterwards
O	816	818	to
O	819	826	surgery
O	826	827	.

O	828	840	Pathological
O	841	849	response
O	850	853	was
O	854	862	measured
O	862	863	.

B-total-participants	864	869	Forty
I-total-participants	870	873	one
O	874	882	patients
O	883	887	were
O	888	896	included
O	897	899	in
O	900	903	our
O	904	909	study
O	909	910	.

O	911	915	They
O	916	920	were
O	921	932	distributed
O	933	935	in
O	936	939	two
O	940	951	homogeneous
O	952	958	groups
O	958	959	:
B-control-participants	960	962	21
O	963	965	in
O	966	969	the
O	970	977	control
O	978	983	group
O	984	987	and
B-intervention-participants	988	990	20
O	991	993	in
O	994	997	the
O	998	1003	study
O	1004	1009	group
O	1009	1010	.

B-outcome	1011	1022	Dimensional
I-outcome	1023	1035	pathological
I-outcome	1036	1044	response
O	1045	1048	was
O	1049	1055	higher
O	1056	1058	in
O	1059	1062	the
O	1063	1068	study
O	1069	1074	group
O	1075	1079	than
O	1080	1082	in
O	1083	1086	the
O	1087	1094	control
O	1095	1098	one
O	1099	1100	(
O	1100	1101	p
O	1102	1103	<
O	1103	1104	0
O	1104	1105	.
O	1105	1107	05
O	1107	1108	)
O	1108	1109	.

B-cv-bin-abs	1110	1114	Five
O	1115	1123	patients
O	1124	1126	in
O	1127	1130	the
O	1131	1138	control
O	1139	1144	group
O	1145	1148	and
B-iv-bin-abs	1149	1152	ten
O	1153	1161	patients
O	1162	1164	of
O	1165	1168	the
O	1169	1174	study
O	1175	1180	group
O	1181	1192	experienced
B-outcome	1193	1201	complete
I-outcome	1202	1214	pathological
I-outcome	1215	1223	response
O	1224	1225	(
O	1225	1226	p
O	1227	1228	<
O	1228	1229	0
O	1229	1230	.
O	1230	1232	05
O	1232	1233	)
O	1233	1234	.

O	1235	1238	The
O	1239	1243	most
O	1244	1250	common
O	1251	1260	secondary
O	1261	1267	events
O	1268	1272	were
B-outcome	1273	1283	leucopenia
O	1283	1284	,
B-outcome	1285	1296	neutropenia
O	1297	1300	and
B-outcome	1301	1306	fever
O	1306	1307	.

B-outcome	1308	1317	Morbidity
O	1317	1318	,
B-outcome	1319	1325	number
I-outcome	1326	1328	of
I-outcome	1329	1334	lymph
I-outcome	1335	1340	nodes
O	1340	1341	,
B-outcome	1342	1349	disease
I-outcome	1349	1350	-
I-outcome	1350	1354	free
I-outcome	1355	1363	survival
O	1364	1367	and
B-outcome	1368	1375	general
I-outcome	1376	1384	survival
O	1385	1388	did
O	1389	1392	not
O	1393	1397	show
O	1398	1409	significant
O	1410	1421	differences
O	1422	1429	between
O	1430	1436	groups
O	1436	1437	.

O	1438	1440	No
B-outcome	1441	1450	mortality
O	1451	1454	was
O	1455	1463	reported
O	1464	1470	during
O	1471	1472	a
O	1473	1480	minimum
O	1481	1487	follow
O	1487	1488	-
O	1488	1490	up
O	1491	1493	of
O	1494	1496	28
O	1497	1503	months
O	1503	1504	.

O	1505	1508	Our
O	1509	1516	results
O	1517	1524	confirm
O	1525	1528	the
O	1529	1542	effectiveness
O	1543	1545	of
O	1546	1555	docetaxel
O	1555	1556	-
O	1556	1566	epirubicin
O	1567	1569	to
O	1570	1576	obtain
B-outcome	1577	1585	complete
I-outcome	1586	1598	pathological
I-outcome	1599	1607	response
O	1607	1608	.

O	1609	1620	Neoadjuvant
O	1621	1628	therapy
O	1629	1632	has
O	1633	1637	been
O	1638	1643	shown
O	1644	1646	to
O	1647	1655	increase
O	1656	1659	the
B-outcome	1660	1672	pathological
I-outcome	1673	1681	response
O	1682	1686	when
O	1687	1688	a
O	1689	1695	taxane
O	1696	1698	is
O	1699	1704	added
O	1705	1707	to
O	1708	1710	an
O	1711	1724	anthracycline
O	1724	1725	.

O	1726	1730	This
O	1731	1742	combination
O	1743	1752	presented
O	1753	1757	more
O	1758	1767	secondary
O	1768	1774	events
O	1774	1775	,
O	1776	1779	but
O	1780	1784	they
O	1785	1788	can
O	1789	1791	be
O	1792	1803	effectively
O	1804	1811	managed
O	1812	1821	medically
O	1821	1822	.

O	1823	1834	Neoadjuvant
O	1835	1844	docetaxel
O	1844	1845	-
O	1845	1855	epirubicin
O	1856	1864	followed
O	1865	1867	by
O	1868	1875	surgery
O	1876	1878	is
O	1879	1881	an
O	1882	1893	appropriate
O	1894	1901	regimen
O	1902	1905	for
O	1906	1914	patients
O	1915	1919	with
O	1920	1927	locally
O	1928	1936	advanced
O	1937	1943	breast
O	1944	1950	cancer
O	1950	1951	.
